Ticker LaunchIPO · IMCR
Immunocore Holdings plc
Formerly Immunocore Ltd
Immunocore Holdings plc (IMCR) priced its initial public offering on Feb 8, 2021 at $26.00 per ADS, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $1.1B. Goldman Sachs was lead-left underwriter, joined by J.P. Morgan and Jefferies. Cooley advised the company and Davis Polk advised the underwriters.
Immunocore Holdings plc is a late-stage biotechnology company developing ImmTAX, a class of TCR bispecific immunotherapies, for cancer, infectious and autoimmune diseases. It has five clinical-stage programs in oncology and infectious disease and has dosed over 600 cancer patients with its candidates.
- Status
- IPO
- Ticker
- IMCR
- Exchange
- Nasdaq Global Select
- Priced
- Feb 8, 2021
- IPO price
- $26.00 per ADS
- Market cap at IPO price
- $1.1B
- First filed
- Jan 15, 2021
- Underwriters
- Goldman Sachs, J.P. Morgan and Jefferies
- Company counsel
- Cooley
- Underwriters' counsel
- Davis Polk
- Sector
- Biotech & pharma
- Country / state
- United Kingdom
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (F-1) first filed Jan 15, 2021
- Latest amendment Feb 3, 2021
- Final prospectus (424B4) Feb 8, 2021
- All filings on EDGAR CIK 1671927
Other Biotech & pharma IPOs in 2021
- Adagene Inc.ADAG · Feb 10, 2021
- Lucira Health, Inc.LHDX · Feb 8, 2021 · $153M
- Pharvaris N.V.PHVS · Feb 8, 2021 · $165.4M
- Terns Pharmaceuticals, Inc.TERN · Feb 8, 2021 · $127.5M
- Vor Biopharma Inc.VOR · Feb 8, 2021 · $176.9M
- Elicio Therapeutics, Inc.ANGN · Feb 5, 2021 · $80M